Westway Health LARS
Long Acting Reactive Species was the first non-antibiotic antimicrobial technology developed by Prof O’Flaherty and Dr McCay. This is a highly effective antimicrobial technology against Gram-negative and Gram-positive organisms. This shows an excellent safety/low toxicity profile in both in vitro and in vivo. LARS can be administered via a number of routes, including aerosolisation/nebulisation and coupled with low MIC concentrations lends itself to a broad range of therapeutic applications.